FEAS
发表于 2025-3-25 05:53:34
entativesfrom different disciplines gather to discuss the recent advances in APS. The conference intends to cover basic aspects of APS, such as pathogenesis, origins, genetics, intracellular and molecular event978-3-319-85662-9978-3-319-55442-6
自传
发表于 2025-3-25 09:17:38
Recent Advances in Understanding of the Genetics of Antiphospholipid Syndrome identify and characterize genes associated with the development of aPL should improve our understanding of this complex autoimmune disorder and regarding which patients with aPL are likely to develop clinical manifestations of the syndrome.
mercenary
发表于 2025-3-25 13:31:08
Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Testsature and conducted new studies between 2013 and 2016; the conclusions were presented at a special session during the 15th International Congress on aPL (., North Cyprus, September 2016). This paper updates our recommendations.
Migratory
发表于 2025-3-25 16:14:55
Prevention and Treatment of Thrombotic Antiphospholipid Syndromem without arterial thrombosis are adequately treated with warfarin administered to a target INR of 2.0–3.0. There is a lack of good-quality evidence to support any particular therapeutic strategy for patients with a history of arterial thrombosis. Standard-intensity warfarin (INR 2.0–3.0) is used in
collagenase
发表于 2025-3-25 20:43:18
Microwave Radiometry and Thermography identify and characterize genes associated with the development of aPL should improve our understanding of this complex autoimmune disorder and regarding which patients with aPL are likely to develop clinical manifestations of the syndrome.
podiatrist
发表于 2025-3-26 01:38:38
Charge in Electromagnetic Wave,ature and conducted new studies between 2013 and 2016; the conclusions were presented at a special session during the 15th International Congress on aPL (., North Cyprus, September 2016). This paper updates our recommendations.
曲解
发表于 2025-3-26 04:38:53
Convexity Properties of Coulomb Systems,m without arterial thrombosis are adequately treated with warfarin administered to a target INR of 2.0–3.0. There is a lack of good-quality evidence to support any particular therapeutic strategy for patients with a history of arterial thrombosis. Standard-intensity warfarin (INR 2.0–3.0) is used in
欢乐中国
发表于 2025-3-26 09:54:59
Book 2017nal Congress on Antiphospholipid Antibodies, held every 3 years, is the venue where representativesfrom different disciplines gather to discuss the recent advances in APS. The conference intends to cover basic aspects of APS, such as pathogenesis, origins, genetics, intracellular and molecular event
懒惰人民
发表于 2025-3-26 13:57:50
http://reply.papertrans.cn/16/1587/158644/158644_29.png
史前
发表于 2025-3-26 20:17:54
http://reply.papertrans.cn/16/1587/158644/158644_30.png